Home
Series of Journals
Literature
Latest literature
Popular literature
About us
Intro
Organizational structure
Editor in Chief
Copyright
Contact us
The title
The title
The keywords
The author
Wuhan University
Zhongnan Hospital of Wuhan University
Center for Evidence-Based and Translational Medicine of Wuhan University
Home
Results
The title
The title
The keywords
The author
A total of
8
result was found. Results that relate to
Cost-utility
Pharmacoeconomic evaluation of Huangkui capsule versus losartan potassium tablets in the treatment of IgA nephropathy
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(1):02-09.
817 times
358 times
Liang-Wen GOU
Zhao-Ting GUO
Qiong LUO
Nan YANG
Ming HU
Huangkui capsule
Losartan potassium tablets
Chronic kidney disease
Pharmacoeconomics
Cost-utility
analysis
Details
Cost-utility analysis of Shenling Baizhu powder in treatment of sarcopenia in older men
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(4):376-383.
896 times
292 times
Huan-Huan JIANG
Hui-Qin SHEN
Zhi-Xiu WANG
Yun-Fei CHEN
Hui GUO
Na XU
Shenling Baizhu powder
Sarcopenia
Cost-utility
analysis
Pharmacoeco-nomics
Details
Cost-utility analysis of sacubitril/valsartan, dapagliflozin and empagliflozin in heart failure with reduced ejection fraction
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(8):878-885.
577 times
242 times
Dan-Dan LU
Sheng-Xiang WANG
Shan LU
Dan PAN
Li-Yuan SHI
Fei-Chuang Jing2
Heart failure with reduced ejection fraction
Sacubitril/valsartan
Dapagliflozin
Empagliflozin
Markov model
Cost-utility
analysis
Details
Cost-utility analysis of budesonide/formoterol powder inhalation versus salmeterol/fluticasone powder inhalation for asthma in adolescents
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(1):60-67.
452 times
295 times
SHEN Anle
WU Bin
LIU Dan
JIANG Yuelian
WU Juan
YIN Yong
ZHANG Shunguo
Budesonide/formoterol
Salmeterol/fluticasone
Cost-utility
analysis
Asthma
Adolescent
Details
Cost-utility analysis of azacitidine versus decitabine in the treatment of myelodysplastic syndrome
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(12):1371-1379.
380 times
178 times
La-Ji DANZENG
Yong-Gong YANG
Si-Liang WANG
Meng-Ying LIU
Azacitidine
Decitabine
Myelodysplastic syndrome
Markov model
Cost-utility
analysis
Pharmacoeconomics
Details
Pharmacoeconomic evaluation of different doses of rivaroxaban for the prevention of thrombosis in patients with nonvalvular atrial fibrillation
Published on
China Pharmacist
2023,36(11):233-240.
334 times
244 times
Wei LUO
Xue-Ying PENG
Dong YANG
Xin-Mei WU
Nonvalvular atrial fibrillation
Rivaroxaban
Dose selection
Markov model
Cost-utility
analysis
Details
Cost-utility analysis of edaravone dexborneol for acute ischemic stroke
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(1):68-74.
393 times
1331 times
ZHOU Shasha
CHEN Xiangfan
CHEN Xia
Edaravone dexborneol
Edaravone
Acute ischemic stroke
Decision tree model
Cost-utility
analysis
Details
Pharmacoeconomic evaluation of glucagon-like peptide-1 receptor agonist combined with metformin in the treatment of type 2 diabetes mellitus
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(4):388-401.
257 times
491 times
YU Tian
LIU Shaohua
WEI Anhua
GUO Jieru
ZHANG Chengliang
LIU Dong
LIU Zhelong
Glucagon-like peptide-1 receptor agonist
Metformin
Type 2 diabetes mellitus
Cost-utility
Markov model
Pharmacoeconomics
Details